Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

pharmareview.files.wordpress.com
from pharmareview.files.wordpress.com More from this publisher
02.06.2013 Views

Reactions Skin Acne (

484 RITUXIMAB (2003): Plosker GL+, Drugs 63(8), 803 (2002): Motto DG+, Isr Med Assoc J 4(11), 1006 Chills (10%) (2006): Antoniu SA, Expert Opin Investig Drugs 15(9), 1115 (2003): Prescrire Int 12(66), 125 (2003): Boye J+, Ann Oncol 14(4), 520 (2003): Fierro MT+, JAmAcadDermatol49, 281 (passim) (2003): Rehwald U+, Blood 101(2), 420 (2002): Salopek TG+, JAmAcadDermatol47(5), 785 Death (2006): Herishanu Y+, Clin Lymphoma Myeloma 6(5), 407 (2006): Iyer A+, Arch Pathol Lab Med 130(10), 1557 (2006): Perceau G+, Br J Dermatol 155(5), 1053 (2006): Scheinfeld N, Dermatol Online J 12(1), 3 (2006): Seifert G+, Haematologica 91(6 Suppl), ECR23 (2003): Sirvent-Von Bueltzingsloewen A+, Med Pediatr Oncol 40(6), 408 (2001): Huhn D+, Blood 98(5), 1326 (2001): Suzan F+, NEnglJMed345(13), 1000 Fever (2006): Cabanillas F+, Ann Oncol 17(9), 1424 (2 cases) (2006): Penalver FJ+, Ann Hematol 85(6), 400 (2006): Tamminga RY+, Pediatr Blood Cancer 47(5 Suppl), 714 (2004): Vieira CA+, Transplantation 77(4), 542 (2003): Prescrire Int 12(66), 125 (2003): Boye J+, Ann Oncol 14(4), 520 (2003): Fierro MT+, JAmAcadDermatol49, 281 (passim) (2003): Rehwald U+, Blood 101(2), 420 Hepatotoxicity (2006): Iyer A+, Arch Pathol Lab Med 130(10), 1557 (2006): Ozgonenel B+, Am J Hematol 81(4), 302 (2006): Sera T+, Intern Med 45(11), 721 (reactivation) Hypersensitivity (2003): Hellerstedt B+, Ann Oncol 14(12), 1792 Infections (2006): Biehn SE+, Hematol Oncol 24(4), 234 (2006): Cabanillas F+, Ann Oncol 17(9), 1424 (18 cases) (2006): El Tal AK+, JAmAcadDermatol55(3), 449 (2002): Motto DG+, Isr Med Assoc J 4(11), 1006 Injection-site burning (2005): Fink-Puches R+, JAmAcadDermatol52(5), 847 Injection-site edema (2006): Perez-Gala S+, Arch Dermatol 142(11), 1516 (2 cases) Injection-site erythema (2005): Fink-Puches R+, JAmAcadDermatol52(5), 847 Injection-site pain (2005): Fink-Puches R+, JAmAcadDermatol52(5), 847 Injection-site pruritus (2006): Perez-Gala S+, Arch Dermatol 142(11), 1516 Injection-site reactions (sic) (2002): Meo P+, Recenti Prog Med 93(7), 421 (2002): Motto DG+, Isr Med Assoc J 4(11), 1006 (2001): Stasi R+, Blood 98(4), 952 (2001): Wood AM, Am J Health Syst Pharm 58(3), 215 Myalgia/Myositis/Myopathy/Myotoxicity (7%) Nephrotoxicity (2006): Scheinfeld N, Dermatol Online J 12(1), 3 Serum sickness (2007): Finger E+, J Clin Rheumatol 13(2), 94 (2007): Todd DJ+, J Rheumatol 34(2), 430 (2006): Schutgens RE, Br J Haematol 135(2), 147 (2006): Tamminga RY+, Pediatr Blood Cancer 47(5 Suppl), 714 (2005): Catuogno M+, Rheumatology (Oxford) 44(3), 406 (2002): Herishanu Y, Am J Hematol 70(4), 329 (2001): D’Arcy CA+, Arthritis Rheum 44, 1717 Upper respiratory infection (2006): Antoniu SA, Expert Opin Investig Drugs 15(9), 1115 RIVASTIGMINE Trade name: Exelon (Novartis) Indications: Alzheimer’s disease and dementia Category: Cholinesterase inhibitor Half-life: 1–2 hours Clinically important, potentially hazardous interactions with: galantamine Reactions Skin Allergic reactions (sic) (~1%) Bullous dermatitis (~1%) Cellulitis (~1%) Clammy skin (~1%) Dermatitis (~1%) Diaphoresis (10%) Edema (~1%) Exanthems (~1%) (2001): Monastero R+, Am J Med 111(7), 583 Exfoliative dermatitis (~1%) Facial edema (~1%) Herpes simplex (~1%) Peripheral edema (~2%) Psoriasis (~1%) Purpura (~1%) Rash (sic) (~2%) Ulcerations (~1%) Urticaria (~1%) Mucosal Gingivitis (~1%) Glossitis (~1%) Sialorrhea (~1%) Ulcerative stomatitis (~1%) Vaginitis (~1%) Xerostomia (~1%) Hair Hair – alopecia (~1%) Eyes Periorbital edema (~1%) Other Hot flashes (~1%) Infections (~2%) Myalgia/Myositis/Myopathy/Myotoxicity (20%) Thrombophlebitis (

Reactions<br />

Skin<br />

Acne (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!